This new study from investigators at Tel Aviv University looked at predictors of nonalcoholic fatty liver disease (NAFLD) among children and adolescents considered obese, because its predictors are not well known in this group.
In this cross-sectional study of 57 pediatric patients with a mean (SD) body mass index (BMI) of 38.8 (9.7) mg/m2, classifying them as obese, a potential link between high BMI and severe liver steatosis was found, thereby indicating weight loss could alleviate hepatic fibrosis risk.
These findings were published recently in BMC Pediatrics.
“In view of the increased prevalence of obesity among children and adolescents, it is of upmost importance to identify young patients at risk for advanced fibrosis who may develop cirrhosis and liver failure,” the authors wrote. “Only few studies have aimed to find predictors for advanced fibrosis in pediatric NAFLD patients.”
All of the children and adolescents included in this subanalysis—part of another study investigating outcomes related to bariatric surgery and dietary intervention—were admitted to the Obesity Clinic at Dana-Dwek Children’s Hospital of the Tel Aviv Medical Center between December 1, 2018, and December 1, 2019; had a BMI above the 95th percentile for their age; and received multidisciplinary care from a gastroenterologist, hepatologist, registered dietitian, and psychologist. They could not have a current primary liver disease diagnosis.
Participants (N = 57; 61% male; 91.9% of Jewish ancestry; 8.1% of Arab ancestry) received advice on 2 fronts: nutritional recommendations, which consisted of a low carbohydrate, low glycemic load, and isocaloric diet (30%-40% carbohydrates, 35%-50% fats, 20%-25% proteins), individualized per patient and calorie requirements, and healthy lifestyle recommendations, such as reducing screen time and engaging in regular physical activity.
The following overall results were seen:
In addition, 17 patients (11 males, 6 females) completed both baseline and 3-month blood tests and elastography, with these results:
The authors write that in light of their findings, there is a great need for early dietary intervention among children classified as obese, and that for those with moderate/severe vs minimal/no fibrosis, intervention may be necessary due to differences in metabolic parameters, “even if no other metabolic disorder is present.”
Possible limitations on the generalizability of the authors’ findings are the lack of liver biopsies, not having a control group, and the 3-month follow-up.
“Longitudinal and larger-cohort studies are needed to compare the effectiveness of a low carbohydrate diet with that of other dietary interventions,” the authors conclude, “for preventing the progression of NAFLD toward more severe forms of liver derangements early in its natural history.”
Reference
Moran-Lev H, Cohen S, Webb M, et al. Higher BMI predicts liver fibrosis among obese children and adolescents with NAFLD – an interventional pilot study. BMC Pediatr. Published online September 3, 2021. doi:10.1186/s12887-021-02839-1
FDA Approves Resmetirom, First Treatment for NASH With Liver Fibrosis
March 14th 2024The first medication for the treatment of nonalcoholic steatohepatitis (NASH) and liver fibrosis received accelerated approval. Previously, the only treatment available to patients was implementing lifestyle changes aimed at weight reduction.
Read More
Discussing Increased Prevalence of NAFLD and NASH, and the Current Lack of Treatments
August 7th 2018Despite how common nonalcoholic fatty liver disease is, there are currently no approved medications on the market. Instead, patients have to rely on lifestyle modification, such as weight loss, increased physical activity, and dietary changes. However, that may change.
Listen
Pathological Neutrophil Migration in Cirrhosis Linked to Increased Risk of AEs
November 30th 2022A more-developed version of the assay used in this study may help manage patients with acute decompensation of liver cirrhosis or acute-on-chronic liver failure before liver transplantation.
Read More
MA Beneficiaries May Be at Disadvantage for Complex Cancer Surgeries
November 21st 2022Patients with Medicare Advantage (MA) were 1.5 times more likely to die within a month of surgical removal of their stomach or liver, and twice as likely to die within a month of oncologic surgery of the pancreas, compared with patients with traditional Medicare.
Read More
Change in Smoking Status and Subsequent BMI Change Linked to NAFLD Risk
November 3rd 2022Across 4 types of smoking status groups, nonalcoholic fatty liver disease (NAFLD) risk significantly increased among participants who saw an increase in body mass index (BMI) and decreased among participants whose BMI went down.
Read More